Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has seen a rise of 1.48% as of January 14, 2026, with a turnover of 2.21% and a transaction volume of 37.37 million yuan [1] - The ETF's latest scale reached 1.671 billion yuan and the latest share count reached 1.883 billion, both hitting record highs since its inception [1] - The 44th JPMorgan Healthcare Conference is being held from January 12 to 15, 2026, in San Francisco, focusing on biotechnology, biopharmaceuticals, and AI in medicine, marking it as a significant investment and trading window for the global pharmaceutical industry [1] Group 2 - Yilian Biotech announced a new exclusive licensing agreement with Roche for the YL201 project, which includes an upfront payment of $570 million and potential milestone payments [2] - Haizhi Science signed a licensing agreement with AirNexis for the HSK39004 project, with a total transaction value exceeding $1 billion, currently in Phase II clinical trials in China [2] - Zhongsheng Peptide has reached a global licensing and collaboration agreement with Novartis for an undisclosed peptide asset in the field of radioligand therapy [2] Group 3 - The Hong Kong Stock Connect Innovative Drug Index aims to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [3] - The top ten weighted stocks in the index include CSPC Pharmaceutical Group, BeiGene, CanSino Biologics, China National Pharmaceutical Group, Innovent Biologics, 3SBio, Hansoh Pharmaceutical, Kelun-Biotech, Kangzheng Pharmaceutical, and Ascentage Pharma-B [3]

Group 1 - The Hong Kong innovative drug sector opened high today, with companies like 3SBio and InnoCare rising by 6%, and CSPC Pharmaceutical and Rongchang Bio increasing by 5%, contributing to a 3.27% rise in the Hong Kong Stock Connect Innovative Drug ETF (159297), which also saw a net subscription of 16 million shares, marking three consecutive days of gains [1][2] - CSPC Pharmaceutical's ActRIIA/B antibody JMT206 injection clinical trial application was approved for obesity treatment, and its self-developed chemical class 1 new drug SYH2061 injection received FDA approval for clinical trials. The company's executive chairman, Cai Dongchen, has increased his holdings by a total of 44.87 million shares in the past month [2] - The Federal Reserve's interest rate cut expectations have risen significantly, with a December rate cut probability now at 80% [2] Group 2 - There has been a significant increase in demand for flu-related medications, testing, and online consultations, with Meituan's platform reporting over a 100% increase in orders for specific flu medications since November. Alibaba Health's platform noted a more than 500% week-on-week increase in the number of buyers for antiviral flu medications in the last two weeks [2] - The Hong Kong Stock Connect Innovative Drug ETF (159297) recently underwent a major update, removing CXO companies to enhance the purity of innovative drugs to 100%. The frequency of sample adjustments has increased from semi-annual to quarterly, allowing for faster updates of constituent stocks [2] - Since its launch on September 22, the ETF has added 1.2 billion shares, achieving a growth rate of 295.26%, with a total management and custody fee rate of 0.2%, making it one of the lowest-cost options in its category, and it allows T+0 trading without QDII quota restrictions [3]

Group 1 - The Hong Kong innovative drug sector has seen a consecutive rise for two days, with BeiGene increasing by 7%, reaching its highest level since November 2021, and other companies like Innovent Biologics and 3SBio also showing significant gains [1] - BeiGene reported Q3 revenue of 10.077 billion yuan, a year-on-year increase of 41.1%, and a net profit attributable to shareholders of 689 million yuan, marking a turnaround from losses [1] - The Southbound Innovative Drug ETF (159297) has recorded a net inflow of 1.053 billion yuan since its launch on September 22, with a growth rate of 285.91% in shares, indicating strong investor interest [1] Group 2 - Guotai Junan Securities highlighted that the full-chain encouragement of innovation policies will further improve medical insurance payments, and the commercial insurance innovative drug catalog is about to be implemented, making innovative products the strongest area in the pharmaceutical sector [2] - In the context of the patent cliff for major products, the business development (BD) transactions of multinational corporations (MNCs) are active, with China becoming the second-largest source of projects for global top 20 MNCs, and BD is expected to reach new highs by 2026 [2]

Group 1 - The Hong Kong stock market has rebounded strongly for two consecutive days, with the Hang Seng Index rising by 1.7% and the Hang Seng Tech Index increasing by 2.7% [1] - The rebound is attributed to the easing of trade tensions and the reduction of panic over U.S. credit issues, leading to a 2.4% increase in the Chinese concept stocks index overnight, with Alibaba and NetEase both rising over 4% [1] - Traders are currently predicting a 99% probability of a Federal Reserve rate cut next week, with another cut expected in December [1] Group 2 - The net inflow of southbound funds and ETF investments into Hong Kong stocks has been significant, with over 45 billion HKD flowing in during October, marking a record high of 1.2 trillion HKD net purchases for the year [1] - The Southern Tech ETF (159269) has seen a net inflow of 1.513 billion HKD since July 25, with the lowest management and custody fees in its category at 0.35% [1] - The Southern Innovative Drug ETF (159297) has experienced continuous net subscriptions since its listing on September 22, with a total net inflow of 478 million HKD and a combined management and custody fee of 0.2%, also the lowest among similar products [1] Group 3 - Guoyuan International believes that the biggest external uncertainty facing the market is the U.S.-China rivalry, which affects investor sentiment and causes short-term market fluctuations [2] - Despite short-term volatility, there is a strong possibility that the Hang Seng Index will return to an upward trend, as ongoing negotiations between the two sides keep overall risk levels manageable [2] - The expectation is that once external disturbances decrease, the Hong Kong stock market will present a better entry opportunity, with a quick recovery anticipated after short-term adjustments [2]

Group 1 - The Hong Kong stock market has rebounded strongly, with the Hang Seng Index rising by 1.7% and the Hang Seng Tech Index increasing by 2.7% [1] - The rebound is attributed to easing trade tensions and reduced credit panic in the U.S., leading to a 2.4% increase in the Chinese concept index overnight, with Alibaba and NetEase both rising over 4% [1] - Traders are anticipating a 99% probability of a Federal Reserve rate cut next week, with another cut expected in December [1] Group 2 - Significant capital inflow into Hong Kong stocks has been observed, with over 45 billion HKD flowing in during October, marking a record high net purchase of 1.2 trillion HKD for the year [1] - The Southern Technology ETF has seen a net inflow of 1.513 billion CNY since July 25, with the lowest management and custody fees in its category [1] - The Southern Innovative Drug ETF has also experienced consistent net subscriptions since its listing on September 22, with a total net inflow of 478 million CNY and the lowest combined management and custody fees [1] Group 3 - The primary external uncertainty facing the market is the U.S.-China rivalry, which affects investor sentiment and causes short-term market fluctuations [2] - Despite short-term volatility, there is a strong possibility that the Hang Seng Index will return to an upward trend, as ongoing negotiations between the two countries keep overall risk levels manageable [2] - A potential agreement may be reached in the future, providing a favorable entry point for investors in the Hong Kong stock market after external disturbances decrease [2]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has shown strong performance, with significant inflows and a focus on the upcoming ESMO conference, highlighting investment opportunities in Chinese innovative pharmaceuticals [1][2] Group 1: ETF Performance - As of October 16, 2025, the Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) increased by 2.63%, with a turnover of 7.19% and a transaction volume of 52.87 million yuan [1] - The ETF's latest scale reached 709 million yuan, with shares totaling 784 million, both hitting record highs since inception [1] - The ETF has seen continuous net inflows over the past nine days, totaling 399 million yuan [1] Group 2: Market Trends and Opportunities - The 2025 European Society for Medical Oncology (ESMO) conference, scheduled for October 17-21 in Berlin, will focus on breakthrough therapies in lung and breast cancer, showcasing the R&D capabilities of Chinese pharmaceutical companies [1] - Huafu Securities believes that the innovative drug sector in China is entering a phase where quantitative changes will lead to qualitative improvements, with a positive outlook for the next 5-10 years driven by business development (BD) overseas, continuous data catalysts, and new product sales [1][2] - CICC highlights that domestic innovative drugs are transitioning from following trends to FIC/BIC innovations, marking a qualitative upgrade in the industry [2] Group 3: Index and Major Stocks - The Hong Kong Stock Connect Innovative Drug ETF closely tracks the National Index of Hong Kong Stock Connect Innovative Drugs, which reflects the performance characteristics of listed companies in the innovative drug sector [2] - The top ten weighted stocks in the index include Baijiazhenshou, Kangfang Biotech, Xinda Biopharma, China Biopharmaceutical, Shiyao Group, Sanofi, Hansoh Pharmaceutical, Kelun-Botai Biotech, Zai Lab, and Rongchang Biotech [2]